Fruit and vegetable processing and food technology: a summary of research

Evaluation of tomato cultivars for processing / W. A. Gould and R. Stillabower -- Physical and subjective color evaluation of tomato juice / Kenneth L. Beck and W. A. Gould -- Flavor evaluation of tomato juice fortified with sugar and citric acid / J. A. Gould and W. A. Gould -- Effects of citric acid and sugar ratios on thermal resistance of Bacillus coagulans var. thermoacidurans in tomato juice / Dennis L. Gierhart and W. A. Gould -- Protein bodies of the germinating tomato seed cotyledon / L. K. Eggers and J. R. Geisman -- Studies concerning the protein of tomato seeds recovered from tomato cannery waste / L. K. Eggers and J. R. Geisman -- Lipid composition of cucumber / A. C. Peng -- Fatty acids in fresh and recycled brines / A. C. Peng and J. R. Geisman -- Repeated recycling of spent pickle brine affects pickle quality / J. R. Geisman and M. Lazear -- Evaluation of snap bean cultivars for processing / W. Gould, J. Gould, J. Mount, M. Skoog and R. Stillabower -- Evaluating strawberries for freezing / J. F. Gallander and J. F. Stetson -- Grapes for Ohio wines / J. F. Gallander and J. F. Stetso

1973 Research Progress Reports, Fruit and Vegetable Processing and Food Technology

Evaluation of snap bean varieties for processing / Wilbur A. Gould -- Evaluation of tomato cultivars for processing / W. A. Gould, James Black, Emily Korensky, Ruth Stillabower, and Stanley Z. Berry -- Commercial tomato cultivar evaluation / Wilbur A. Gould, Jerry Wright, in cooperation with Stanley Berry, Marion White, Tip Top Canning Co., Beckman and Gast Company and Hirzel Canning Co. -- Relationship of USDA D6 tomato colorimeter to AGTRON E-5 / Wilbur A. Gould and Jerry Wright -- Effects of food additives on the quality of canned tomatoes / Wilbur A. Gould, Jacquelyn Gould, and James Black -- Effects of food additives on the quality of canned tomato juice / Wilbur A. Gould, Ruth Stillabower, Jacquelyn Gould and James Black -- Retention of ascorbic acid in fortified tomato juice ; Effect of storage time and temperature and added ascorbic acid on the total acid and pH of tomato juice / Gerald G. Pope and Wilbur A. Gould -- Cell wall components and tomato juice consistency / David E. Crean -- Lipid content of cabbage & sauerkraut / Andrew C. Peng -- Canned rice-tomatoes / Teung Chin and Wilbur A. Gould -- Development of a canned pecan pie filling / W. A. Gould and S. Perryman -- A new soybean food from tempeh / Nasruddin Iljas, Wilbur A. Gould and Andrew C. Peng -- Rehabilitation and recycling spend cucumber pickling brines / J. R. Geisman and R. E. Henne -- Evaluation of several grape cultivars for wine making / James F. Gallande

1976 Research Progress Reports; Fruit and Vegetable Processing and Food Technology

Evaluation of tomato cultivars for processing / W. A. Gould, R. Stillabower and D. Grindell -- Using tomato seeds / J. R. Geisman -- Evaluation of snap bean cultivars for processing / W. A. Gould and R. Stillabower -- Flame sterilization of canned green beans / J. R. Mount and W. A. Gould -- Flame sterilization of canned peas / J. R. Ice, J. R. Mount and W. A. Gould -- Flame sterilization of other canned products / John Mount and W. A. Gould -- Determination of factors affecting heat penetration in flame sterilized canned whole kernel sweet corn / R. Joseph and W. A. Gould -- Geotrichum candidum: the new FDA indicator of plant sanitation for the food processing industry / J. G. Fox and W. A. Gould -- Recycling spent pickling brines ; Uses for the outer green leaves of cabbage / J. R. Geisman -- The development of a fish spread by the utilization of freshwater drum from Lake Erie / J. D. Morgan and W. A. Gould -- Development of a sausage product from Lake Erie freshwater drum / S. Hauck and W. A. Gould -- Utilization of Lake Erie freshwater drum for fish sticks / W. Stone and W. A. Gould -- Acidification and thermal processing of tripolyphosphate treated freshwater drum fillets / T. F. Chin and W. A. Gould -- Effect of lipid and fatty acid composition on keeping quality / Andrew C. Peng -- Grape lipids / P. A. Higgins and A. C. Peng -- The effect of maturation on the lipid content of 'Concord' grapes / John A. Bauman and James F. Gallander -- Stability of ascorbic acid in fortified apple juice / M. I. Mahmoud and W. A. Gould -- Wine deacidification with mixed cultures of Schizosaccharomyces pombe and Saccharomyces cerevisiae ; The effect of bacterial inoculum on malo-lactic fermentation in wines ; Concentrations of tartaric and malic acids of several wine varieties grown in Ohio / J. F. Gallander and J. F. Stetso

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved

Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure

This article provides a detailed overview of the rationale for key aspects of the protocol of the Digitalis Investigation Group (DIG) trial. It also highlights unusual aspects of the study implementation and the baseline characteristics. The DIG trial is a large, simple, international placebo-controlled trial whose primary objective is to determine the effect of digoxin on all cause mortality in patients with clinical heart failure who are in sinus rhythm and whose ejection fraction is less than or equal to 0.45. An ancillary study examines the effect in those with an ejection fraction > 0.45. Key aspects of the trial include the simplicity of the design, broad eligibility criteria, essential data collection, and inclusion of various types of centers. A total of 302 centers in the United States and Canada enrolled 7788 patients between February 1991 and September 1993. Follow-up continued until December 1995 with the results available in Spring 1996